Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
572 confirmed programs
· 222 sponsors
· Last scored 2026-04-02
90.7
Signal Score
✓ FDA Inspections (5)
✓ Clinical Trials (572)
✓ SEC Filings (13)
○ Press
✓ EMA GMP (1)
✓ MHRA GMP (1)
Quick Facts: Bristol Myers Squibb (CGT Mfg)
- Signal Score
- 90.7/100 (as of 2026-04-02)
- Quality Compliance
- 96.9/100
- Headquarters
- Bothell, WA · Warren, NJ
- Modalities
- CAR-T, Cell Therapy
- Active Programs
- 572 confirmed from ClinicalTrials.gov across 222 sponsors
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
Signal Score & Pillar Breakdown
Quality Compliance
96.9
FDA Inspections5 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2025-07-18)
EMA GMP Certificates1 on record
MHRA GMP Certificates1 on record
Operations
95.3
572 active programs across 222 sponsors
Modalities: Cell Therapy, CAR-T
415 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
572 active programs across 222 sponsors · Modalities: Cell Therapy, CAR-T · 415 programs in advanced phases (Phase 2/3)
Programs
572
Sponsors222
ModalitiesCAR-T, Cell Therapy
572 active programs across 222 sponsors
Modalities: Cell Therapy, CAR-T
415 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07388277
CC-97540 in Patients With Antineutrophil Cytoplasmic...
PHASE1/PHASE2
Not Yet Recruiting
NCT07105059
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
PHASE1
Recruiting
View all 572 programs →
Source: ClinicalTrials.gov · Retrieved Apr 05, 2026
Financial Stability
89.0
Publicly traded — financial transparency
Strong industry presence in SEC filings (166 mentions)
Major facility investment disclosed in SEC filings
Multiple manufacturing risk factors in SEC filings
Source: SEC EDGAR, press monitoring
13 SEC filings with industry mentions on record
SEC Filings13 with industry mentions
Publicly traded — financial transparency
Strong industry presence in SEC filings (166 mentions)
Major facility investment disclosed in SEC filings
Multiple manufacturing risk factors in SEC filings
Capacity
76.0
3 manufacturing sites
10 facility investment mentions in SEC filings
Sites: Bothell, WA, Warren, NJ, Devens, MA
Source: SEC EDGAR, press monitoring, company profiles
3 manufacturing sites
3 manufacturing sites
10 facility investment mentions in SEC filings
FDA Inspection History
2025-07
2025-07
2024-12
2024-09
2024-09
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2025-07-18 | Summit, New Jersey | Human Cellular, Tissue, and Gene Therapies | No | Voluntary Action Indicated (VAI) |
| 2025-07-08 | Devens, Massachusetts | Drug Quality Assurance | No | Voluntary Action Indicated (VAI) |
| 2024-12-06 | Summit, New Jersey | Bioresearch Monitoring | Yes | Voluntary Action Indicated (VAI) |
| 2024-09-24 | Bothell, Washington | Human Cellular, Tissue, and Gene Therapies | No | No Action Indicated (NAI) |
| 2024-09-06 | Summit, New Jersey | Bioresearch Monitoring | No | No Action Indicated (NAI) |
Source: FDA Data Dashboard · Retrieved Apr 05, 2026
EMA GMP Compliance 1 certificates
2026-02
Compliant
Non-Compliant
| Certificate | Site | Country | Inspection Date | Status |
|---|---|---|---|---|
| CRN00GYR3/IMP13128/00001 | Bristol-Myers Squibb Services Unlimited Company | Ireland | 2026-02-10 | COMPLIANT |
Source: EMA EudraGMDP · Retrieved Apr 05, 2026
MHRA GMP Compliance 1 certificates
2014-08
Compliant
Non-Compliant
| Certificate | Site | City / Postcode | Inspection Date | Status |
|---|---|---|---|---|
| UK GMP 14758 Insp GMP 14758/5575-0003[H] | CELGENE CORPORATION | 07901 | 2014-08-21 | COMPLIANT |
Source: MHRA GMDP Database · Retrieved Apr 05, 2026
Clinical Activity 572 studies
NCT07388277
CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
PHASE1/PHASE2
Not Yet Recruiting
NCT07335562
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacaptagene-...
PHASE3
Not Yet Recruiting
NCT07361497
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent...
PHASE3
Recruiting
NCT07361510
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in...
PHASE3
Recruiting
NCT07333261
Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
PHASE1
Recruiting
NCT07465029
A Study of Incidence, Treatment Patterns, and Outcomes in...
NA
Active Not Recruiting
NCT07100080
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for...
PHASE2/PHASE3
Recruiting
NCT06855771
A Study of BMS-986504 in Participants With Pre-treated Advanced or...
PHASE2
Recruiting
NCT07018752
A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral...
PHASE1/PHASE2
Recruiting
NCT07105059
A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma
PHASE1
Recruiting
NCT06767956
Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With...
PHASE1/PHASE2
Not Yet Recruiting
NCT07141563
A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in...
NA
Completed
NCT06094842
Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific...
PHASE1
Withdrawn
NCT06764771
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants...
PHASE1
Active Not Recruiting
NCT06708949
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs....
PHASE2
Recruiting
NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard...
PHASE3
Recruiting
NCT06773910
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage...
PHASE2
Recruiting
NCT06523621
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
PHASE2
Recruiting
NCT06646276
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+...
PHASE3
Recruiting
NCT06697197
A Study of BMS-986482 Alone or as Combination Therapy in Participants With...
PHASE1/PHASE2
Recruiting
+ 552 more studies
Source: ClinicalTrials.gov · Retrieved Apr 05, 2026
Financial Intelligence
"Our platforms are comprised of chemically-synthesized or small molecule drugs including protein degraders, drugs produced from biological processes, called “biologics”, ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics."
"CAR-T cell therapies are administered by intravenous infusion."
"Breyanzi
®
Breyanzi
(lisocabtagene maraleucel) is a CD19-directed genetically modified autologous CAR-T cell therapy indicated for the treatment of adult patients with relapsed or refractory LBCL after one or more lines of systemic therapy, including DLBCL not otherwise specified, high-grade B-cell lymphoma, primary mediastinal LBCL, grade 3B FL and relapsed or refractory FL after at least two prior lines of systemic therapy, relapsed or refractory CLL or SLL; relapsed or refractory MCL in patie"
"The acquisition will provide BMS with full rights to OTX-201, a preclinical
in vivo
CAR T-cell therapy currently in IND-enabling studies for autoimmune disease."
"rights to
Abecma
, a cell therapy for the treatment of adult patients with relapsed or refractory multiple myeloma."
"In October 2025, BMS entered into a definitive agreement to acquire Orbital Therapeutics, which will provide the Company with full rights to OTX-201, a preclinical
in vivo
CAR T-cell therapy currently in IND-enabling studies for autoimmune disease."
"rights to
Abecma
, a cell therapy for the treatment of adult patients with relapsed or refractory multiple myeloma."
"Breyanzi
(lisocabtagene maraleucel) — a CD19-directed genetically modified autologous CAR-T cell therapy indicated for the treatment of adult patients with relapsed or refractory LBCL after one or more lines of systemic therapy, including DLBCL not otherwise specified, high-grade B-cell lymphoma, primary mediastinal LBCL, grade 3B FL and relapsed or refractory FL after at least two prior lines of systemic therapy, relapsed or refractory CLL or SLL, and relapsed or refractory MCL in patients who "
"Abecma
(idecabtagene vicleucel) — is a BCMA genetically modified autologous CAR-T cell therapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cyclic ADP ribose hydrolase monoclonal antibody."
"rights to
Abecma
, a cell therapy for the treatment of adult patients with relapsed or refractory multiple myeloma."
"Breyanzi
(lisocabtagene maraleucel) — a CD19-directed genetically modified autologous CAR-T cell therapy indicated for the treatment of adult patients with relapsed or refractory LBCL after one or more lines of systemic therapy, including DLBCL not otherwise specified, high-grade B-cell lymphoma, primary mediastinal LBCL, grade 3B FL and relapsed or refractory FL after at least two prior lines of systemic therapy, relapsed or refractory CLL or SLL, and relapsed or refractory MCL in patients who "
"revenues increased 133% during the first quarter of 2025 primarily due to higher demand enabled by expanded manufacturing capacity, new indication launches and higher average net selling prices."
"Our platforms are comprised of chemically-synthesized or small molecule drugs including protein degraders; drugs produced from biological processes, called “biologics”; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics."
"CAR-T cell therapies are administered by intravenous infusion."
"2
Breyanzi
®
Breyanzi
(lisocabtagene maraleucel) is a CD19-directed genetically modified autologous CAR-T cell therapy indicated for the treatment of adult patients with relapsed or refractory LBCL after one or more lines of systemic therapy, including DLBCL not otherwise specified, high-grade B-cell lymphoma, primary mediastinal LBCL, grade 3B FL and relapsed or refractory FL after at least two prior lines of systemic therapy, relapsed or refractory CLL or SLL, and relapsed or refractory MCL in"
"These changes primarily include (i) transforming R&D operations to accelerate pipeline delivery, (ii) enhancing our commercial operating model, and (iii) establishing a more responsive manufacturing network and expanding our cell therapy manufacturing capabilities."
"Our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases in the following core therapeutic areas: oncology and hematology with novel modalities in cell therapies, protein degraders, ADCs and radiopharmaceuticals; immunology with a focus on establishing new standards of care in pulmonology, rapidly advancing cell therapy into immunology diseases and transformational programs to control inflammation, reset immune memory and promote homeo"
"In addition, year-to-date, we have achieved significant advances in CAR-T cell therapy with the approval of
Breyanzi
in the U.S."
"These changes primarily include (i) transforming R&D operations to accelerate pipeline delivery, (ii) enhancing our commercial operating model, and (iii) establishing a more responsive manufacturing network and expanding our cell therapy manufacturing capabilities."
"Our focus is on discovering, developing and delivering transformational medicines for patients facing serious diseases in the following five core therapeutic areas: (i) oncology with a priority in certain tumor types, including diversification beyond IO; (ii) hematology with opportunities to expand leadership position in multiple myeloma, as well as broaden our portfolio across leukemias, lymphomas and non-malignant hematologic diseases; (iii) immunology with a focus in dermatology, rheumatology"
"In 2024, we achieved significant advances in CAR-T cell therapy with the approval of
Breyanzi
in the U.S."
"These changes primarily include (i) transforming R&D operations to accelerate pipeline delivery (ii) enhancing our commercial operating model, and (iii) establishing a more responsive manufacturing network and expanding our cell therapy manufacturing capabilities."
"Our focus is on discovering, developing and delivering transformational medicines for patients facing serious diseases in the following five core therapeutic areas: (i) oncology with a priority in certain tumor types, including diversification beyond IO; (ii) hematology with opportunities to expand leadership position in multiple myeloma, as well as broaden our portfolio across leukemias, lymphomas and non-malignant hematologic diseases; (iii) immunology with a focus in dermatology, rheumatology"
"In 2024, we achieved significant advances in the CAR-T cell therapy arena with the approval of
Abecma
in the U.S."
Source: SEC EDGAR · Retrieved Apr 05, 2026
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 92.2
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.5
CAR-T, Cell Therapy
WuXi Biologics
Shanghai, CN · Wuxi, CN
Signal Score: 82.9
CAR-T, Cell Therapy, AAV
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 80.2
CAR-T, Cell Therapy, AAV, Lentiviral
RoslinCT
Edinburgh, UK · Hopkinton, MA
Signal Score: 80.2
CAR-T, Cell Therapy, iPSC, Gene Editing